Navigation Links
CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis

LA JOLLA, Calif., Feb. 17, 2011 /PRNewswire/ -- CalciMedica, a biotechnology company developing small molecules to treat inflammatory and autoimmune diseases, today announced that it has dosed the first cohort in a Phase 1 clinical trial of CM2489. CM2489 is a first-in-class calcium-release activated calcium (CRAC) channel inhibitor being studied as a once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.  In addition, the company announced that this milestone has triggered an additional $6 million tranche of financing from all existing investors, which include Sanderling Ventures, SR One and Biogen Idec New Ventures. The current financing will enable CalciMedica to complete its ongoing Phase 1 clinical trial by third quarter 2011.  

The randomized, placebo-controlled, blinded, single-ascending dose study is being conducted at a single site in the US under an Investigational New Drug (IND) application recently allowed by the FDA and will enroll 48 healthy volunteers through multiple cohorts. The goal of the study is to determine the safety, tolerability and pharmacokinetic profile of CM2489 in humans and to select doses for investigation in subsequent studies.

The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel.

"CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CCIs have the potential to be safe and effective drugs to treat multiple chronic inflammatory and autoimmune diseases," said Gonul Velicelebi, Ph.D., president and CEO of CalciMedica. "We are targeting psoriasis as our first proof-of-concept indication and are considering rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, asthma, and multiple sclerosis for our follow-on indications."

"CRAC channels have been a drug target sought by the pharmaceutical industry for many years. These channels and the discovery of selective inhibitors that can safely modulate the immune system have been elusive," said Peter McWilliams, Ph.D., chairman of the CalciMedica board of directors and managing director at Sanderling Ventures.  "The team at CalciMedica has done a phenomenal job of identifying the channel components, discovering small molecules that inhibit the channel and bringing this pioneering approach into the clinic."

About CalciMedica

CalciMedica, a privately-held small molecule discovery and development company, has a portfolio of first-in-class drug candidates that inhibit the calcium-release activated calcium (CRAC) channel and that have the potential to treat chronic inflammatory and autoimmune diseases. The company's lead drug candidate, CM2489, is under development for the treatment of moderate-to-severe plaque psoriasis. The company has exclusive intellectual property rights to STIM and Orai proteins that constitute the CRAC channel as well as the novel compounds that inhibit the CRAC channel activity. CalciMedica's investors are Sanderling Ventures, SR One and Biogen Idec New Ventures.  For more information, visit

SOURCE CalciMedica
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CalciMedica Appoints Evelyn Graham to its Board of Directors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Board ... the Company welcomes Neil Woodford,s call for ... internet report on NW Bio.  The Company,s Board is ... stated, "We agree with Mr. Woodford that, at ...
(Date:11/27/2015)... United Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt ... biopharmaceutical company, announced today that it has closed the ... (CMDS) business to Guerbet (GBT- NYSE Euronext) in a ... operations encompassed four manufacturing facilities and a total of ... 75 in the St. Louis ...
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
Breaking Biology Technology:
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
Breaking Biology News(10 mins):